Press Releases

Date	Title	Company
11-Oct-2023	In-vivo Imaging Market is expected to reach USD 1459.71 million by 2030	The Wire Times
11-Oct-2023	Alosetron Market Industry Share, Size, Growth, Demands, Revenue, Top Leaders and Application	The Wire Times
11-Oct-2023	LECTIS (CARBOHYDRATE BINDING PROTEINS) Market By Emerging Trends, Business Strategies, Developing Technologies, Revenue and Competitive Landscape	The Wire Times
11-Oct-2023	Chronic Kidney Disease (CKD) Market would rocket up to USD 18,800.17 million by 2030	The Wire Times
11-Oct-2023	MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus	MinervaX
11-Oct-2023	The hidden scars: Stigmatisation a major impact of skin diseases across Europe	European Dermatology-Venereology Society
11-Oct-2023	First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)	Businesswire
11-Oct-2023	OMass Therapeutics Announces its Attendance at Upcoming Conferences and Events	OMass Therapeutics
11-Oct-2023	Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis	Bristol Myers Squibb
11-Oct-2023	Roche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions	Roche
11-Oct-2023	Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis	Businesswire
11-Oct-2023	Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies	Roche
11-Oct-2023	Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions	Businesswire
11-Oct-2023	First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity	Businesswire
11-Oct-2023	Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis	Novo Nordisk
11-Oct-2023	AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023	AbbVie
11-Oct-2023	Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease	Merck
11-Oct-2023	Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)	Merck
11-Oct-2023	TheraVet: BIOCERA-VET in Horse Bone Cysts Highlighted at an International Equine Conference in the USA	Businesswire
11-Oct-2023	3D Bioprinting Market Poised to Exceed US$ 6.5 Billion by 2033 Through Tissue Engineering Innovations	MARKITWIRED